Table 1.

Evaluation of tolerability of treatment regimens combining talazoparib and temozolomide in nude mice implanted with GBM12 cells

#Tumor locationDose and scheduleSurvival after 1 week of first doseSurvival after 4 weeks of first doseMaximum weight loss
1OrthotopicTMZ: 50 mg/kg, d1–5, q28d + TAL: 0.025 mg/kg, bid, d1–5, q28d0/50/523%
2OrthotopicTMZ: 30 mg/kg, d1–5, q28d + TAL: 0.05 mg/kg, bid, d1–5, q28d0/50/524%
3OrthotopicTMZ: 5 mg/kg, d1–5, q28d + TAL: 0.05 mg/kg, bid, d1–5, q28d5/54/51%
4OrthotopicTMZ: 5 mg/kg, d1–5, q28d + TAL: 0.075 mg/kg, bid, d1–5, q28d5/53/56%
5FlankTMZ: 5 mg/kg, d1–5, q7d + TAL: 0.15 mg/kg, bid, d1–5, q7d7/74/716%
6FlankTMZ: 5 mg/kg, d1–5, q14d + TAL: 0.15 mg/kg, bid, d1–5, q14d11/1110/117%
  • Abbreviations: bid, twice daily; TAL, talazoparib; TMZ, temozolomide.